Treatment of Pyoderma Gangrenosum.

Neutrophil Pyoderma gangrenosum Review Therapy Treatment Ulcer

Journal

Dermatologic clinics
ISSN: 1558-0520
Titre abrégé: Dermatol Clin
Pays: United States
ID NLM: 8300886

Informations de publication

Date de publication:
Apr 2024
Historique:
medline: 1 3 2024
pubmed: 1 3 2024
entrez: 29 2 2024
Statut: ppublish

Résumé

Pyoderma gangrenosum is a rare neutrophilic dermatosis that results in painful cutaneous ulcers and is frequently associated with underlying hematologic disorders, inflammatory bowel disease, or other autoimmune disorders. Pathogenesis involves an imbalance between proinflammatory and anti-inflammatory mediators, leading to tissue damage from neutrophils. First-line treatment options with the greatest evidence include systemic corticosteroids, cyclosporine, and tumor necrosis factor alpha inhibitors. Other steroid-sparing therapies such as dapsone, mycophenolate mofetil, intravenous immunoglobulin, and targeted biologic or small molecule inhibitors also have evidence supporting their use. Wound care and management of underlying associated disorders are critical parts of the treatment regimen.

Identifiants

pubmed: 38423680
pii: S0733-8635(23)00107-9
doi: 10.1016/j.det.2023.12.002
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

183-192

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure The authors have nothing to disclose.

Auteurs

Marcus G Tan (MG)

Division of Dermatology, University of Ottawa, 737 Parkdale Avenue, 4th Floor Dermatology, Ottawa, ON K1Y1J8, Canada. Electronic address: marcusg.tan@gmail.com.

Stanislav N Tolkachjov (SN)

Mohs Micrographic & Reconstructive Surgery, Epiphany Dermatology, Department of Dermatology, Baylor University Medical Center, University of Texas at Southwestern, Texas A&M University School of Medicine, 1640 FM 544, Suite 100, Lewisville, TX 75056, USA.

Classifications MeSH